Provided by Tiger Trade Technology Pte. Ltd.

Inhibikase Therapeutics, Inc.

2.50
+0.11004.60%
Post-market: 2.530.0280+1.12%19:51 EDT
Volume:735.93K
Turnover:1.83M
Market Cap:350.00M
PE:-5.78
High:2.54
Open:2.41
Low:2.35
Close:2.39
52wk High:2.54
52wk Low:1.33
Shares:140.00M
Float Shares:64.52M
Volume Ratio:1.58
T/O Rate:1.14%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.4327
EPS(LYR):-0.4909
ROE:-51.96%
ROA:-32.79%
PB:2.28
PE(LYR):-5.09

Loading ...

Company Profile

Company Name:
Inhibikase Therapeutics, Inc.
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
35
Office Location:
1000 N. West Street,Suite 1200,Wilmington,Delaware,United States
Zip Code:
19801
Fax:
- -
Introduction:
Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a small molecule Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, University of Bordeaux, and Michigan State University, as well as University of California; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Directors

Name
Position
Mark Iwicki
Chief Executive Officer and Director
Amit Munshi
Director and Chairperson of the Board
Arvind Kush
Director
David Canner
Director
Dennis Berman
Director
Roberto Bellini
Director
Vincent Aurentz
Director

Shareholders

Name
Position
Mark Iwicki
Chief Executive Officer and Director
David McIntyre
Chief Financial Officer
Chris Cabell
Head of Research and Development and President